Medicare Part D Use and Costs for Immune-Mediated Neurologic Therapies

What were the trends in the use of and Medicare Part D payments for disease-modifying therapies (DMTs) for immune-mediated neurologic diseases from 2013 to 2022?In this economic analysis of 63 unique drugs used for DMTs, those for immune-mediated neurologic diseases accounted for a 3.8% increase in total Medicare Part D claims; however, total payments for these therapies rose disproportionately by 70.3%, with expenditures significantly exceeding estimated medical care and prescription drug inflation adjustments.Although DMT use for immune-mediated neurologic diseases has remained stable, associated costs have increased substantially beyond inflation, suggesting other contributors to rising expenditures.

Corresponding Author: Ka-Ho Wong, MBA, University of Utah School of Medicine, 175 N Medical Dr, Salt Lake City, UT 84132 (ka-ho.wong@hsc.utah.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.